01/25/23 7:30 AMNYSE : ANVS clinical triallow floatANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASEAnnovis Bio, Inc., a clinical-stage drug platform company addressing neurodegenerative diseases, today provided a patient enrollment update for the Company's ongoing Phase 3 study of buntanetap for the treatment of Parkinson's disease. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: "We are very pleased with the pace of enrollment...RHEA-AIneutral
01/06/23 7:30 AMNYSE : ANVS managementlow floatAnnovis Bio Announces New Appointments to Strengthen Its Senior Leadership TeamAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as ViceRHEA-AIvery positive
11/08/22 5:35 PMNYSE : ANVS low floatAnnovis Bio Announces Third Quarter 2022 Results and Provides Corporate UpdateAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recentRHEA-AIneutral
10/20/22 7:30 AMNYSE : ANVS conferenceslow floatAnnovis Bio to Present at the 2022 ThinkEquity Investor Conference(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the ThinkEquity 2022 Investor Conference on Wednesday, October 26, 2022, in NewRHEA-AIneutral
10/11/22 7:30 AMNYSE : ANVS clinical triallow floatAnnovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's DiseaseAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer'sRHEA-AIneutral
10/06/22 7:30 AMNYSE : ANVS clinical triallow floatAnnovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's DiseaseAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study ofRHEA-AIvery positive
09/29/22 7:30 AMNYSE : ANVS conferenceslow floatAnnovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29,RHEA-AIneutral
09/13/22 7:30 AMNYSE : ANVS low floatAnnovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publication of three granted US patents – US11400075 ( link), US11376238 ( link), and US11382893 (RHEA-AIneutral
09/08/22 7:30 AMNYSE : ANVS low floatAnnovis Bio's CEO Maria Maccecchini Issues Letter to StockholdersAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today released the following letter to stockholders from its Chief Executive Officer Dr. MariaRHEA-AIneutral
08/29/22 4:00 PMNYSE : ANVS managementlow floatAnnovis Bio Appoints Henry Hagopian III as Chief Financial OfficerAnnovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately. Mr. HagopianRHEA-AIvery positive